Is bio stock a good buy?

[Read more] According to 3 analysts, the average rating for BIO stock is "Strong Buy." The 12-month stock price forecast is $481.33, which is an increase of 50.07% from the latest price. After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

What are bio share price targets?

Their BIO share price targets range from $524.00 to $550.00. On average, they predict the company's share price to reach $533.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View analysts price targets for BIO or view top-rated stocks among Wall Street analysts. How have BIO shares performed in 2023?

Is Bio-Rad Laboratories a good stock to buy?

The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $533.00, Bio-Rad Laboratories has a forecasted upside of 75.5% from its current price of $303.62. Bio-Rad Laboratories has received no research coverage in the past 90 days.

Is Bio-Rad Laboratories stock underperforming the S&P500?

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24... Get a real-time Bio-Rad Laboratories, Inc. (BIO) stock price quote with breaking news, financials, statistics, charts and more.